DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION

Molecure S.A.

WSE:MOC Stock Report

Market Cap: zł152.1m

  • Company Overview
    • Valuation
    • Future Growth
    • Past Performance
    • Financial Health
    • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

Molecure Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Marcin Szumowski

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership0.7%
Management average tenure5.7yrs
Board average tenure4.5yrs

Recent management updates

Recent updates

Analysis Article • Sep 06

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Aug 20

Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Apr 20

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Dec 01

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Jul 07

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 10

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Aug 16

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 04

OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

OncoArendi Therapeutics S.A.'s ( WSE:OAT ) robust earnings report didn't manage to move the market for its stock. Our...
Analysis Article • Feb 24

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Every investor in OncoArendi Therapeutics S.A. ( WSE:OAT ) should be aware of the most powerful shareholder groups...
Analysis Article • Jan 02

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, OncoArendi...

CEO

Marcin Szumowski

no data
Tenure
zł367,206
Compensation

Dr. Marcin Jan Szumowski, Ph D., is employed at Life Science Innovations Fund. He has been Chief Executive Officer and President of the Management Board at Molecure S.A. (formerly known as OncoArendi Thera...


Leadership Team

NamePositionTenureCompensationOwnership
Marcin Szumowski
Co-Founderno datazł367.21k0.66%
PLN 997.5k
Zbigniew Zaslona
Chief Scientific Officer & Member of Management Board4.7yrszł367.21k0.18%
PLN 272.2k
Agnieszka Rajczuk-Szczepanska
HR Director6.7yrszł271.21kno data
Adam Golebiowski
Co-Founder & VP of Research Chemistry14.7yrszł500.00kno data
Jacek Olczak
Co-Founder & Head of Medicinal Chemistryno datano datano data
Monika Czarnecka
Finance Director1.7yrsno datano data
Magdalena Tyszkiewicz
Head of CMC6.7yrsno datano data
Dariusz Stencel
Chief Medical Officerless than a yearno datano data
5.7yrs
Average Tenure

Experienced Management: MOC's management team is seasoned and experienced (5.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Robert Oskard
Member of the Supervisory Boardless than a yearno datano data
Luke O'Neill
Member of Scientific Advisory Boardno datano datano data
Bart Lambrecht
Member of Scientific Advisory Boardno datano datano data
Tomasz Piec
Vice Chairman of the Supervisory Board6.7yrszł129.06kno data
Douglas Hay
Member of Scientific Advisory Boardno datano datano data
Paul Van Der Horst
Independent Chairman of the Supervisory Board4.7yrszł154.87k0.049%
PLN 73.8k
Nancy Van Osselaer
Independent Member of the Supervisory Board4.7yrszł129.06kno data
Pawel Trawkowski
Independent Member of the Supervisory Board4.3yrszł129.06kno data
Piotr Iwanowski
Member of Scientific Advisory Boardless than a yearzł122.47k0.097%
PLN 147.6k
4.5yrs
Average Tenure
59.5yo
Average Age

Experienced Board: MOC's board of directors are considered experienced (4.5 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 07:18
End of Day Share Price 2026/09/14 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Molecure S.A. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Beata Szparaga-WasniewskaBiuro maklerskie mBanku
Lukasz KosiarskiIpopema Securities S.A.
Dawid GórzynskiPKO BP Securities

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide